Hasil Pencarian - Andre Rogatko

  • Menampilkan 1 - 12 hasil dari 12
Perbaiki Hasil
  1. 1
    Number of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control

    Number of Patients per Cohort and Sample Size Considerations Using Dose Escalation with Overdose Control oleh Mourad Tighiouart, André Rogatko

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels

    Dose Finding in Oncology Trials Guided by Ordinal Toxicity Grades Using Continuous Dose Levels oleh Mourad Tighiouart, André Rogatko

    Diterbitkan 2024-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Escalation with overdose control using time to toxicity for cancer phase I clinical trials.

    Escalation with overdose control using time to toxicity for cancer phase I clinical trials. oleh Mourad Tighiouart, Yuan Liu, André Rogatko

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical Trials

    Escalation with Overdose Control Using Ordinal Toxicity Grades for Cancer Phase I Clinical Trials oleh Mourad Tighiouart, Galen Cook-Wiens, André Rogatko

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Comparison between continuous and discrete doses for model based designs in cancer dose finding.

    Comparison between continuous and discrete doses for model based designs in cancer dose finding. oleh Márcio Augusto Diniz, Mourad Tighiouart, André Rogatko

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control

    Incorporating a Patient Dichotomous Characteristic in Cancer Phase I Clinical Trials Using Escalation with Overdose Control oleh Mourad Tighiouart, Galen Cook-Wiens, André Rogatko

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding

    Escalation with Overdose Control is More Efficient and Safer than Accelerated Titration for Dose Finding oleh André Rogatko, Galen Cook-Wiens, Mourad Tighiouart, Steven Piantadosi

    Diterbitkan 2015-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer.

    Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer. oleh Christine S Walsh, Mitchell Kamrava, Andre Rogatko, Sungjin Kim, Andrew Li, Ilana Cass, Beth Karlan, Bobbie J Rimel

    Diterbitkan 2021-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Visualizing adverse events in clinical trials using correspondence analysis with R-package visae

    Visualizing adverse events in clinical trials using correspondence analysis with R-package visae oleh Márcio A. Diniz, Gillian Gresham, Sungjin Kim, Michael Luu, N. Lynn Henry, Mourad Tighiouart, Greg Yothers, Patricia A. Ganz, André Rogatko

    Diterbitkan 2021-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study.

    Convergent RANK- and c-Met-mediated signaling components predict survival of patients with prostate cancer: an interracial comparative study. oleh Peizhen Hu, Leland W K Chung, Dror Berel, Henry F Frierson, Hua Yang, Chunyan Liu, Ruoxiang Wang, Qinlong Li, Andre Rogatko, Haiyen E Zhau

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30

    Toxicity Index, patient-reported outcomes, and persistence of breast cancer chemotherapy-associated side effects in NRG Oncology/NSABP B-30 oleh N. Lynn Henry, Sungjin Kim, Ron D. Hays, Marcio A. Diniz, Mourad Tighiouart, Gillian Gresham, Michael Luu, Reena S. Cecchini, Greg Yothers, André Rogatko, Patricia A. Ganz

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells.

    Inhibition of β2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells. oleh Sajni Josson, Yasuhiro Matsuoka, Murali Gururajan, Takeo Nomura, Wen-Chin Huang, Xiaojian Yang, Jin-Tai Lin, Roger Bridgman, Chia-Yi Chu, Peter A Johnstone, Majd Zayzafoon, Peizhen Hu, Haiyen Zhau, Dror Berel, Andre Rogatko, Leland W K Chung

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: